高结核/HIV负担国家抗结核治疗中依非韦伦的药代动力学:系统综述
该系统综述纳入1990至2016年间在高结核/HIV负担国家开展的22项研究,评估依非韦伦(EFV)与利福平-异烟肼(RH)联用时的药代动力学。结果显示抗结核药联用对EFV暴露、疗效和安全性影响较小,支持当前EFV 600 mg与抗结核药联用的剂量。
要点
- 抗结核药联用对EFV暴露、疗效和安全性影响较小。
- 支持当前EFV 600 mg与抗结核药联用的剂量。
- CYP2B6 516G>T多态性与较高EFV血浆浓度相关。
核心结论
- 抗结核药联用对非洲和亚洲TB-HIV共感染患者的EFV暴露、疗效和安全性影响较小。
- 支持当前EFV 600 mg与抗结核药联用的剂量。
研究设计与样本
- 系统综述,检索1990至2016年间在高TB/HIV负担国家开展的研究。
- 共检索到119条记录,最终纳入22项研究(其中2项在儿童中开展)。
- 两名评价者独立完成文章筛选和数据收集。
主要发现
- 19项研究中RH中位或平均浓度在1000至4000 ng ml-1的治疗范围内。
- 12项研究(含1项儿童研究)中RH亚治疗浓度患者比例为3.1%至72.2%。
- 6项成人研究和1项儿童研究中RH超治疗浓度患者比例为19.6%至48.0%。
- 8项研究中有5项报告病毒学抑制率>80%。
- 2项和3项研究分别显示任何级别肝毒性和中枢神经系统不良事件与EFV/RH相互作用相关。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: Efavirenz (EFV) and rifampicin-isoniazid (RH) are cornerstone drugs in human immunodeficiency virus (HIV)-tuberculosis (TB) coinfection treatment but with complex drug interactions, efficacy and safety challenges. We reviewed recent data on EFV and RH interaction in TB/HIV high-burden countries. METHODS: We conducted a systematic review of studies conducted in the high TB/HIV-burden countries between 1990 and 2016 on EFV pharmacokinetics during RH coadministration in coinfected patients. Two reviewers conducted article screening and data collection. RESULTS: Of 119 records retrieved, 22 were included (two conducted in children), reporting either EFV mid-dose or pre-dose concentrations. In 19 studies, median or mean concentrations of RH range between 1000 and 4000 ng ml-1 , the so-called therapeutic range. The proportion of patients with subtherapeutic concentration of RH ranged between 3.1 and 72.2%, in 12 studies including one conducted in children. The proportion of patients with supratherapeutic concentration ranged from 19.6 to 48.0% in six adult studies and one child study. Five of eight studies reported virological suppression >80%. The association between any grade hepatic and central nervous system adverse effects with EFV/RH interaction was demonstrated in two and three studies, respectively. The frequency of the CYP2B6 516G > T polymorphism ranged from 10 to 28% and was associated with higher plasma EFV concentrations, irrespective of ethnicity. CONCLUSIONS: Anti-TB drug coadministration minimally affect the EFV exposure, efficacy and safety among TB-HIV coinfected African and Asian patients. This supports the current 600 mg EFV dosing when coadministered with anti-TB drugs.
引用
- Atwine D, Bonnet M, Taburet AM, et al. Pharmacokinetics of efavirenz in patients on antituberculosis treatment in high human immunodeficiency virus and tuberculosis burden countries: A systematic review. Br J Clin Pharmacol. 2018. PMID: 29624706. doi:10.1111/bcp.13600
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。